Unique facial contouring; collagen-building product; treatment lasts up
to two years
LAVAL, QC, April 4 /CNW/ - Sculptra(TM), the first volumizing agent of
its kind, represents a new category in non-invasive cosmetic dermatology for
Canadians who are interested in facial rejuvenation and enhancement with
minimal maintenance and long-lasting results. In addition to smoothing
wrinkles, Sculptra(TM) replaces lost facial volume caused by natural aging and
Unlike currently available products that use fillers to temporarily
correct skin imperfections and require periodic office visits for refresher
sessions, Sculptra(TM) works progressively by restoring volume and by
naturally stimulating the body to produce its own collagen, resulting in a
more natural-looking, youthful appearance that can last up to two years.(1)
With Sculptra(TM), typically three treatment sessions over a two-to-three
month period may be necessary to obtain the desired results. There is no
requirement for pre-treatment skin testing.
"The arrival of Sculptra(TM) is great news because it represents a unique
niche in facial rejuvenation that yields smoother, longer-lasting results,"
says Dr. Sheldon Pollack, dermatologist and director of the Toronto Cosmetic
Skin Surgery Centre. "Sculptra(TM) has been used in the cosmetic dermatology
field since 1999 in more than 30 countries. It's a safe, long-lasting,
non-surgical option for Canadians aged 40+ wanting to significantly reverse
the effects of aging by several years."
Sculptra(TM) has a broad cosmetic application and is suitable for
increasing the volume of depressed areas, particularly to correct skin
depressions - such as skin creases, wrinkles, folds, scars, eye rings - and
for aging skin. It is also suitable for large volume corrections of fat loss
mainly due to normal aging. Injected below the surface of the skin in the area
of fat loss, Sculptra(TM) provides a gradual and significant increase in skin
firmness, improving the appearance of folds and sunken areas. Injections can
only be performed by a trained physician and the treatment involves minimal
"As we age, we lose volume in our face. Sculptra(TM) allows us to restore
the fullness of a more youthful face; think about the analogy of a raisin and
a grape," says Dr. Julie Khanna, plastic surgeon and director of the Institute
of Cosmetic & Laser Surgery in Oakville, Ontario. "Clients who have tried
Sculptra(TM) say they now look as young as they feel and are pleased to see
that Scultpra(TM) delivers on its promise of natural-looking results and a
restored, youthful appearance."
Sculptra(TM) is a synthetic polymer from the alpha-hydroxy acid family
(fruit acids) that is biocompatible, biodegradable and has been widely used
for more than 30 years in dissolvable sutures and soft-tissue implants.(2)
Possible side effects of Sculptra(TM) may include the delayed formation of
small papules under the skin in the treated area particularly when the product
is over-concentrated. These papules are generally not visible and may only be
noticed when pressing on the treated area. Other side effects may include
injection-related events at the site of injection, such as bleeding,
tenderness or discomfort, redness, bruising or swelling.
For more information, visit www.sculptra.ca. The new website also
includes a search tool to easily locate a local Sculptra(TM)-trained physician
across Canada. Health Canada approved Sculptra(TM) in June 2006 and more than
70 dermatologists and plastic surgeons across Canada have been treating
patients since the fall of 2006. Sculptra(TM) is marketed by Dermik, the
dermatology division of sanofi-aventis Canada Inc.
Sanofi-aventis is one of the world's leading pharmaceutical companies.
Backed by a world-class R&D organization, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular, thrombosis,
oncology, metabolic diseases, central nervous system, internal medicine, and
vaccines. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York
(NYSE : SNY). In Canada, sanofi-aventis Canada Inc. employs over 1,140 people
and has its headquarters in Laval, Quebec.
(1) Vleggaar D,. Facial Volumetric Correction with Injectable
Poly-L-Lactic Acid. Dermatol Surg. 2005; 31:1511-1518.
(2) Thioly-Bensoussan, D. Journal of the European Academy of Dermatology
and Venereology. 2006; Vol 20: 14.
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
the CNW Photo Network and archived at http://photos.newswire.ca.
Additional archived images are also available on the CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited
members of the media/
For further information:
For further information: Martha McKimm, Jessica Kasparian, Manning
Selvage & Lee, (416) 967-3702, Martha.firstname.lastname@example.org,
Jessica.email@example.com; Pamela Pavlik, sanofi-aventis Canada Inc., (514)